Vita 34 AG: Proposed resolution to the Annual General Meeting on the suspension of the dividend
May 05, 2020 at 07:50 am EDT
Share
DGAP-Ad-hoc: Vita 34 AG / Key word(s): Dividend
Vita 34 AG: Proposed resolution to the Annual General Meeting on the suspension of the dividend
05-May-2020 / 13:48 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DISCLOSURE OF AN INSIDE INFORMATION ACC. TO ARTICLE 17 MAR
Proposed resolution to the Annual General Meeting on the suspension of the dividend
Leipzig, 5 May 2020 - The Management Board and the Supervisory Board of Vita 34 AG, Leipzig (ISIN: DE000A0BL849; WKN: A0BL84) (the "Company") have proposed in the annual financial statements for the 2019 financial year published on 23 March 2020 to distribute a dividend of ? 0.16 per share, unchanged from the previous year.
The Management Board and Supervisory Board regard the continuity of dividend payments as a key objective. The 2019 financial year was very successful for the Vita Group. However, against the background of the global SARS-CoV-2 pandemic and its economic consequences, the Management Board and Supervisory Board are cautious and propose that the dividend for the 2019 financial year be suspended. This should help to secure liquidity, competitiveness and jobs in the Company even in times of crisis.
The Management Board and the Supervisory Board have therefore decided today to propose to the Annual General Meeting that the balance sheet profit of EURO 1,530,184.01 reported in the annual financial statements of Vita 34 AG as of 31 December 2019 be transferred in full to other revenue reserves.
Notifying persons: Dr. Wolfgang Knirsch (CEO), Falk Neukirch (CFO)
05-May-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
Language:
English
Company:
Vita 34 AG
Deutscher Platz 5a
04103 Leipzig
Germany
Phone:
+49(0341)48792-40
Fax:
+49(0341)48792-39
E-mail:
ir@vita34.de
Internet:
www.vita34.de
ISIN:
DE000A0BL849
WKN:
A0BL84
Listed:
Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
Vita 34 International AG is a Germany-based company engaged in the medical technology sector. The Company is involved in the long-term storage and processing of stem cells from human umbilical cord blood. The cells are collected at the childâs birth and can be used later in his or her life for the treatment of many diseases, such as anemia, diabetes, degenerative joint diseases, cancer, neurological deficits after brain injuries, cartilage damages and others. They also allow the growing of whole organs, such as the liver. On average, one out seven individuals, whose cells are stored, receives autologous stem cell transplant by the age of 70. The Company acts as a cord blood bank and is also engaged in research activities in the area of regenerative medicine, including curing the consequences of strokes and heart attacks. The Company operates in Germany, Spain and Denmark.
VITA 34 AG 
